At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 650 enrolled
Drug / intervention
Ranibizumab 0.5mg +1 moredrug
Likely dose
Ranibizumab 0.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-month, Phase 3b, Randomized, Visual Acuity Assessor-masked, Multicenter Study Assessing the Efficacy and Safety of Ranibizumab 0.5mg in Treat and Extend Regimen Compared to Monthly Regimen, in Patients With Neovascular Age-related Macular Degeneration
In Brief
A Phase 3 clinical trial evaluating Ranibizumab 0.5mg for Age-related Macular Degeneration and Choroidal Neovascularization. Completed, enrolled 650 participants across 91 sites in 19 countries.
Detailed Summary
This study was designed to evaluate the efficacy and safety of two different regimens of 0.5 mg ranibizumab given as intravitreal injection in patients with neovascular age-related macular degeneration
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Chile, Croatia, Denmark, Egypt, Germany, Hungary, India, Israel, Italy, Portugal, Russia, Slovakia, Slovenia, South Korea, Spain, Switzerland, Turkey (Türkiye), United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 2013
Enrollment StartDec 2013
Primary CompletionNov 2015
TodayJul 2026
First PostedSep 24, 2013
Enrollment StartDec 17, 2013
Primary CompletionNov 19, 2015
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 12.8 years ago
Interventions
Ranibizumab 0.5mgdrug
0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
Ranibizumab 0.5mgdrug
0.5 mg ranibizumab (intravitreal injections) prefilled syringe)